BCL2 and cancer: Combining drugs that target proapoptotic BCL-2 family proteins with BRAF inhibitors in BRAFV600E-mutated cancers sensitizes melanoma cells to apoptosis but has not been shown to reverse resistance that is acquired over time [60].